(lp0
S'Intercept Pharmaceuticals Inc Risk Points versus Health Care CML News - 20 hours ago This is a scatter plot analysis of the critical risk points from the option market for Intercept Pharmaceuticals Inc  compared to its own past and the Health Care ETF.'
p1
aS'Intercept Pharmaceuticals  Q4 2016 Results - Earnings Call Transcript Seeking Alpha - Feb 23, 2017 Thank you for joining the Intercept Pharmaceuticals 2016 Full Year Financial Results Conference Call. At this time, all participants are in listen-only mode.Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and ... - GlobeNewswire Oppenheimer Reiterates Outperform Rating and $200 PT on Intercept ... - StreetInsider.com'
p2
aS"Intercept Pharmaceuticals Inc  Stock Could Be Biotech's Grand Slam Investorplace.com - Jan 24, 2017 The market has begun 2017 trading sideways, but don't let that fool you into thinking there aren't opportunities out there, especially in biotech."
p3
aS"This Analyst Bullish On Intercept Pharmaceuticals Inc  Long-Term Smarter Analyst - Feb 10, 2017 Intercept Pharmaceuticals Inc  shares rose as much as 9% during Friday's trading session, after the drug maker announced changes to its ongoing Ocaliva Phase 3 trial in NASH that increase probability of completing enrollment for interim&nbsp;...Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid ... - GlobeNewswire Is Intercept Pharmaceuticals Inc  Stock A Buy After OCA Update? - BNL Finance   "
p4
aS"Analyst Views On Top Movers In Recent Trade: Intercept Pharmaceuticals, Inc ... Post Analyst - 16 hours ago The company's consensus rating on Reuter's scale remained unchanged from 2.86 to 2.86 during a month. Analysts set a 12-month price target of $18.4 a share."
p5
aS"Oppenheimer Holdings Comments on Intercept Pharmaceuticals Inc's FY2020 ... Chaffey Breeze - 21 hours ago Intercept Pharmaceuticals logo Intercept Pharmaceuticals Inc  - Research analysts at Oppenheimer Holdings decreased their FY2020 EPS estimates for shares of Intercept Pharmaceuticals in a research note issued on Thursday, according to&nbsp;...Intercept Pharmaceuticals, Inc.  Broker Price Targets For The ... - Fiscal Standard"
p6
aS'Charles Payne on Biotech: Biogen Inc , Intercept Pharmaceuticals Inc  Investorplace.com - Nov 29, 2016 Still, I am not interested in chasing drug names, as most of the large pharmaceutical companies have thin product pipelines and aging blockbusters.'
p7
aS"Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and ... GlobeNewswire  - Nov 3, 2016 NEW YORK, Nov. 03, 2016  -- Intercept Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today&nbsp;...Intercept Pharmaceuticals'  CEO Mark Pruzanski on Q3 2016 Results ... - Seeking AlphaIntercept  Reports Narrower-Than-Expected Q3 Loss November 03, 2016 - Zacks.com"
p8
aS"Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for ... Yahoo Finance - Mar 3, 2017 LONDON, UK / ACCESSWIRE / March 3, 2017 / Active Wall St. blog coverage looks at the headline from Intercept Pharmaceuticals, Inc.  as the Company announced on March 01, 2017, that UK's National Institute for Health and Care&nbsp;..."
p9
aS"Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva ... GlobeNewswire  - Oct 14, 2016 NEW YORK, Oct. 14, 2016  -- Intercept Pharmaceuticals, Inc.  , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases&nbsp;...Intercept's liver drug gets conditional backing of EMA panel - ReutersIntercept's Ocaliva Gets CHMP Nod in Europe  - Investopedia"
p10
a.